[{"data":1,"prerenderedAt":157},["ShallowReactive",2],{"drug-molnupiravir":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":64,"warnings":65,"renal":73,"monitoring":74,"interactions":75,"review":76,"examples":79,"atc":86,"iran":88,"links":100,"populations":113},"molnupiravir",1,{"fa":7,"en":8},"مولنوپیراویر","Molnupiravir","anti-infectives",{"fa":11,"en":12},"آنالوگ نوکلئوزید ضد SARS-CoV-2","Nucleoside analogue (SARS-CoV-2)",[14],{"name":15,"market":16},"Lagevrio","US",[18,19,7],"lagevrio","لاگوریو",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"cap-200","capsule","oral","200 mg capsule",{"amount":27,"unit":28,"perUnit":23,"scored":29},200,"mg",false,[16],[32],{"source":33,"section":34},"fda-lagevrio","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":50,"durationDays":53,"notes":55},"covid","covid-19",{"fa":40,"en":41},"کووید-۱۹ خفیف تا متوسط پرخطر بزرگسال (مجوز اضطراری) — ۸۰۰ mg هر ۱۲ ساعت، ۵ روز","Mild-to-moderate COVID-19 at high risk, adults (EUA) — 800 mg every 12 h for 5 days",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":48,"dosesPerDay":49},800,2,[51],{"source":33,"section":52},"2.1",{"min":54,"max":54},5,[56],{"text":57,"refs":60},{"fa":58,"en":59},"هرچه زودتر و ظرف ۵ روز از شروع علائم. تنظیم کلیوی یا کبدی ندارد. فقط با مجوز استفاده اضطراری (EUA).","As soon as possible and within 5 days of symptom onset. No renal or hepatic adjustment. Emergency Use Authorization only.",[61,62],{"source":33,"section":52},{"source":33,"section":63},"2.2",[],[66],{"text":67,"refs":70},{"fa":68,"en":69},"سمیت جنینی (در بارداری توصیه نمی‌شود؛ پیشگیری حین درمان و ۴ روز بعد)؛ حساسیت؛ سمیت استخوان و غضروف (زیر ۱۸ سال نه).","Embryo-fetal toxicity (not recommended in pregnancy; contraception during and 4 days after); hypersensitivity; bone and cartilage toxicity (not under 18).",[71],{"source":33,"section":72},"5",[],[],[],{"status":77,"reviewer":78,"date":78},"unverified",null,[80],{"regimen":37,"formulation":22,"input":81,"expect":84},{"ageYears":82,"weightKg":83},60,75,{"perDose":48,"tabletsPerDoseRounded":85},4,[87],"J05AB18",{"status":89,"forms":90,"refs":95},"registered",[91],{"code":92,"en":93,"fa":94},"52942","MOLNUPIRAVIR CAPSULE ORAL 200 mg","کپسول مولنوپیراویر ۲۰۰ میلی‌گرم",[96],{"source":97,"section":98,"url":99},"darooyab-generic","G-4311\u002FMolnupiravir","https:\u002F\u002Fwww.darooyab.ir\u002FG-4311\u002FMolnupiravir",[101,105,108,111],{"kind":102,"url":103,"label":104},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=1b0da643-ab23-4a0b-a9ec-a434522446d0","FDA Lagevrio (EUA)",{"kind":106,"url":107,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa622027.html",{"kind":109,"url":110,"label":87},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AB18",{"kind":112,"url":99,"label":8},"darooyab",{"pregnancy":114,"lactation":123,"pediatric":131,"geriatric":140,"reproductive":149},{"level":115,"text":116,"quote":119,"refs":120},"avoid",{"fa":117,"en":118},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Based on findings from animal reproduction studies, LAGEVRIO may cause fetal harm when administered to pregnant individuals.",[121],{"source":33,"section":122},"Boxed Warning",{"level":115,"text":124,"quote":127,"refs":128},{"fa":125,"en":126},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Based on the potential for adverse reactions in the infant from LAGEVRIO, breastfeeding is not recommended during treatment with LAGEVRIO and for 4 days after the final dose.",[129],{"source":33,"section":130},"8.2",{"level":132,"text":133,"quote":136,"refs":137},"caution",{"fa":134,"en":135},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of LAGEVRIO have not been established in pediatric patients [see Warnings and Precautions (5.3) and Nonclinical Toxicology (13.2) ] .",[138],{"source":33,"section":139},"8.4",{"level":141,"text":142,"quote":145,"refs":146},"ok",{"fa":143,"en":144},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dosage adjustment is recommended based on age.",[147],{"source":33,"section":148},"8.5",{"level":132,"text":150,"quote":153,"refs":154},{"fa":151,"en":152},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Advise individuals of childbearing potential to use a reliable method of contraception correctly and consistently, as applicable for the duration of treatment and for 4 days after the last dose of LAGEVRIO [see Warnings and Precautions (5.1) ].",[155],{"source":33,"section":156},"8.3",1792444706741]